Nucleophilic Defense Against PM Toxicity (NEAT Trial)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

299 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-01

Study Completion Date

2022-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Carnosine is a naturally occurring peptide found in high levels in skeletal muscle and the brain and is also available commercially as a dietary supplement. Since carnosine has anti-oxidant properties and air pollution exposure induces a state of oxidative stress, the purpose of this study is to see if those taking carnosine as a dietary supplement are protected from air pollution-induced oxidative stress and adverse cardiovascular outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function

NCT03151239

Glucose Metabolism Disorders

COMPLETED NA

Effects of Dietary Supplements on Response to Air Pollution

NCT01488656

Inflammation

COMPLETED NA

The Use of L-arginine to Mitigate the Cardiovascular Effects of Exposure to Traffic-related Air Pollution

NCT03433963

Blood Pressure Cardiac Ischemia

COMPLETED NA

Clinical Trial on Rapid Immune Modulating Effects

NCT07206407

Immune Surveillance

RECRUITING NA

Multi-Nutrient Supplement for Radio-Protection

NCT04781868

Oxidative Stress DNA Damage, Radiation Induced Radiation Exposure

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a placebo controlled, randomized, double-blind, interventional trial investigating the efficacy of carnosine in reducing the effects of particulate matter air pollution (PM2.5). A total of 240 participants from the Louisville metropolitan and neighboring areas will be randomized into two dietary supplement study groups - carnosine (n=120) versus placebo (n=120). Intervention of study dietary supplements will occur from May through September, when the levels of PM2.5.are highest in the Louisville, KY area. Study participants will be given a daily oral dose of total of 2 grams of carnosine (or placebo) for a total of 12 consecutive weeks (during May through September).

Urinary levels of carnosine will be used to screen and identify potential candidates with low carnosine levels. Those with levels less than the median levels of the population, will be invited to participate in the study. The following measurements will be performed - blood and urine sample collection, physical examination, arterial stiffness, physical function, and self-reported surveys on environmental exposure, sleep, diet, and exercise. Supplement intervention (carnosine or placebo) will be initiated at the time of Baseline Assessment and will continue for 12 weeks from that date. Two follow up visits will occur at 6 weeks and 12 weeks respectively after initiating supplementation.

This innovative clinical investigation will provide an insight into the pre and post intervention effects of a cheap, safe, and over-the-counter available dietary supplement in countering the effects of air pollution.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Air Pollution Toxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

placebo controlled, randomized, double-blind

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

double blind (participant, investigator)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intervention group

Each participant will be given a daily oral dose of 2 grams of carnosine for 12 weeks

Group Type ACTIVE_COMPARATOR

L-carnosine

Intervention Type DIETARY_SUPPLEMENT

a naturally occurring di-peptide

placebo group

Each participant will be given a daily oral dose of 2 grams of placebo for 12 weeks

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

an identically appearing supplement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L-carnosine

a naturally occurring di-peptide

Intervention Type DIETARY_SUPPLEMENT

placebo

an identically appearing supplement

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Individuals between 22-65 years of age of either gender and all ethnicities,
2. All genders and all ethnicities
3. Residing in or near the Louisville metropolitan area
4. Consumes some type of meat/fish at least once a month during the past 3 months
5. Carnosine levels below the median level of the population
6. Agrees to complete all study visits and follow study intervention regimen
7. Will be living in the study area throughout the study period, with no more than 1 week away from the study area.

Exclusion Criteria

1. Consumed any dietary supplement more than 3 times per week in the past 4 weeks (one month)
2. Current / ongoing treatment for substance abuse
3. Currently undergoing treatment or have conditions which may cause participant to be immunosuppressed
4. Diseases Affecting Peripheral Cell Count (i.e. Autoimmune Diseases - Hashimoto, Rheumatoid Arthritis, SLE, Rheumatoid Arthritis, Sjogren syndrome, Ankylosing Spondylitis, Takayasu arteritis, Kawasaki disease, Polyarteritis nodosa.)
5. Diseases Affecting Bone Marrow capacity
6. Diagnosis of any active cancer
7. Recent organ / kidney transplant or replacement (Active/Long-Term Medications)
8. Type 1 Diabetes Mellitus
9. Untreated thyroid disease
10. Untreated anemia
11. Current acute infections (Influenza, fever, etc.)
12. HIV positive status
13. Active/current Hepatitis HepA, HepB or HepC or in past 6 months
14. Currently or planning to be Pregnant / lactating
15. Prisoners / vulnerable populations
16. Other medical conditions that compromise completion of study
17. Unwilling to provide consent

Minimum Eligible Age

22 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes